179 related articles for article (PubMed ID: 10919405)
1. Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients.
Scandella DH
Semin Thromb Hemost; 2000; 26(2):137-42. PubMed ID: 10919405
[TBL] [Abstract][Full Text] [Related]
2. New characteristics of anti-factor VIII inhibitor antibody epitopes and unusual immune responses to Factor VIII.
Scandella D
Semin Thromb Hemost; 2002 Jun; 28(3):291-6. PubMed ID: 12098091
[TBL] [Abstract][Full Text] [Related]
3. Human factor VIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed factor VIII activation: a new anti-factor VIII inhibitory mechanism.
Nogami K; Shima M; Nishiya K; Sakurai Y; Tanaka I; Giddings JC; Saenko EL; Yoshioka A
Thromb Haemost; 2002 Mar; 87(3):459-65. PubMed ID: 11916079
[TBL] [Abstract][Full Text] [Related]
4. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM
Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
[TBL] [Abstract][Full Text] [Related]
5. Phage display technology: a tool to explore the diversity of inhibitors to blood coagulation factor VIII.
Voorberg J; van den Brink EN
Semin Thromb Hemost; 2000; 26(2):143-50. PubMed ID: 10919406
[TBL] [Abstract][Full Text] [Related]
6. Inhibitor antibodies to factor VIII and factor IX: management.
Lusher JM
Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
[TBL] [Abstract][Full Text] [Related]
7. Identification of plasma antibody epitopes and gene abnormalities in Japanese hemophilia A patients with factor VIII inhibitor.
Sugihara T; Takahashi I; Kojima T; Okamoto Y; Yamamoto K; Kamiya T; Matsushita T; Saito H
Nagoya J Med Sci; 2000 May; 63(1-2):25-39. PubMed ID: 10911718
[TBL] [Abstract][Full Text] [Related]
8. Altered serum factor VIII-related antigen (VIII : AGN)/von Willebrand factor (VIII : vWf) in haemophiliacs with inhibitors to factor VIII procoagulant activity (VIII : C).
Ballard JO; Sanders JC; Eyster ME
Thromb Haemost; 1981 Feb; 45(1):68-72. PubMed ID: 6166064
[TBL] [Abstract][Full Text] [Related]
9. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
Yada K; Nogami K; Shima M
Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
[TBL] [Abstract][Full Text] [Related]
10. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies.
Scandella D
Vox Sang; 1999; 77 Suppl 1():17-20. PubMed ID: 10529680
[TBL] [Abstract][Full Text] [Related]
11. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
Astermark J
Haemophilia; 2006 Dec; 12 Suppl 6():8-13; discussion 13-4. PubMed ID: 17123388
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain.
Laub R; Di Giambattista M; Fondu P; Brackmann HH; Lenk H; Saenko EL; Felch M; Scandella D
Thromb Haemost; 1999 Jan; 81(1):39-44. PubMed ID: 9974372
[TBL] [Abstract][Full Text] [Related]
13. Biosynthesis, assembly and secretion of coagulation factor VIII.
Kaufman RJ; Pipe SW; Tagliavacca L; Swaroop M; Moussalli M
Blood Coagul Fibrinolysis; 1997 Dec; 8 Suppl 2():S3-14. PubMed ID: 9607108
[TBL] [Abstract][Full Text] [Related]
14. Correlation between factor VIII genotype and inhibitor development in hemophilia A.
Fakharzadeh SS; Kazazian HH
Semin Thromb Hemost; 2000; 26(2):167-71. PubMed ID: 10919409
[TBL] [Abstract][Full Text] [Related]
15. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.
Shima M; Scandella D; Yoshioka A; Nakai H; Tanaka I; Kamisue S; Terada S; Fukui H
Thromb Haemost; 1993 Mar; 69(3):240-6. PubMed ID: 7682339
[TBL] [Abstract][Full Text] [Related]
16. Dominant C2 domain epitope specificity of inhibitor antibodies elicited by a heat pasteurized product, factor VIII CPS-P, in previously treated hemophilia A patients without inhibitors.
Sawamoto Y; Prescott R; Zhong D; Saenko EL; Mauser-Bunschoten E; Peerlinck K; van den Berg M; Scandella D
Thromb Haemost; 1998 Jan; 79(1):62-8. PubMed ID: 9459325
[TBL] [Abstract][Full Text] [Related]
17. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.
Scandella DH; Nakai H; Felch M; Mondorf W; Scharrer I; Hoyer LW; Saenko EL
Thromb Res; 2001 Mar; 101(5):377-85. PubMed ID: 11297754
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution.
van den Brink EN; Timmermans SM; Turenhout EA; Bank CM; Fijnvandraat K; Voorberg J; Peters M
Thromb Haemost; 1999 May; 81(5):723-6. PubMed ID: 10365744
[TBL] [Abstract][Full Text] [Related]
19. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
[TBL] [Abstract][Full Text] [Related]
20. [Immune coagulation disorders (excluding antiphospholipid syndrome].
Arai M
Rinsho Byori; 2001 Oct; 49(10):1000-4. PubMed ID: 11769464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
